November 18, 2017

Virus-triggered exacerbation in allergic asthmatic children: neutrophilic airway inflammation and alteration of virus sensors characterize a subgroup of patients

 
OPEN ACCESS
  • Antoine DeschildreEmail author,
  • Muriel Pichavant,
  • Ilka Engelmann,
  • Carole Langlois,
  • Elodie Drumez,
  • Guillaume Pouessel,
  • Sophie Boileau,
  • David Romero-Cubero,
  • Irina Decleyre-Badiu,
  • Anny Dewilde,
  • Didier Hober,
  • Véronique Néve,
  • Caroline Thumerelle,
  • Stéphanie Lejeune,
  • Clémence Mordacq and
  • Philippe GossetEmail authorView ORCID ID profile
Respiratory Research201718:191
Abstract
Background
Viruses are important triggers of asthma exacerbations. They are also detected outside of exacerbation. Alteration of anti-viral response in asthmatic patients has been shown although the mechanisms responsible for this defect remain unclear. The objective of this study was to compare in virus-infected and not-infected allergic asthmatic children, aged 6 to 16 years, admitted to hospital for a severe exacerbation, the innate immune response and especially the expression of pattern recognition receptor (PRR) and their function.

Effect of an Intervention to Promote Breastfeeding on Asthma, Lung Function, and Atopic Eczema at Age 16 Years

Key Points
Question  Does prolonged and exclusive breastfeeding reduce the risk of asthma and atopic eczema and improve lung function in adolescence?

November 16, 2017

Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis



Authors

  • Wenhui WeiPeter Anderson, Abhijit Gadkari, Stuart Blackburn, Rachel Moon, James Piercy, Shashank Shinde, Jorge Gomez, Eric Ghorayeb
  • DOI: 10.1111/1346-8138.14116  View/save citation
  • Abstract
    Since control of atopic dermatitis (AD) remains challenging but has not been adequately characterized, the objective of this study was to characterize disease control among patients with a history of moderate to severe AD.

November 13, 2017

Adherence with epinephrine autoinjector prescriptions in primary care

 
OPEN ACCESS

  • Elissa M. AbramsEmail author,
  • Alexander G. Singer,
  • Lisa Lix,
  • Alan Katz,
  • Marina Yogendran and
  • F. Estelle R. Simons
Abstract
Background
The aim of this study was to estimate primary adherence for epinephrine autoinjector (EA) prescriptions in primary care practices in Manitoba, Canada.

November 6, 2017

Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational study

BMJ 2017; 359 doi: https://doi.org/10.1136/bmj.j4619 (Published 26 October 2017)

Cite this as: BMJ 2017;359:j4619
  1. Jessica J Liu, internist and assistant professor2,
  2. Chaim M Bell, internist and professor1 2 3 4,
  3. John J Matelski, biostatistician2,
  4. Allan S Detsky, internist and professor1 2 3,
  5. Peter Cram, internist and professor1 2 3 4
    Author affiliations
  1. Correspondence to: J J Liu Department of Medicine, Division of General Internal Medicine, University Health Network and Sinai Health System, Toronto, Ontario, Canada jessica.liu@uhn.ca

EAACI Guidelines on Allergen Immunotherapy (AIT)

EAACI has a long history and strong ethos in implementing the latest research findings to deliver better healthcare for patients with allergies. Over the last decades this mission has become even more important with allergic diseases now affecting the lives of millions of people around the world. This represents a major burden for patients as well as their clinicians, governments, legislators and regulators. The current challenge is to deliver appropriate treatments that are able to prevent lifetime disabilities, shifting from “treating a disease“ to “promote health” in a sustainable context.



download ait guidelines web
Allergen immunotherapy (AIT) has been used for a century. Several terms including “desensitization”, “hyposensitization“ and “vaccines” have been used, and often misused, to indicate administration of incremental doses of allergenic substances to reduce the clinical manifestations of allergy. However AIT has also been the subject of considerable controversy in terms of its efficacy. The dispute has impacted on the dissemination of knowledge about AIT, the availability of the products in many countries and the relevant policies for their reimbursement. Some of these issues result from an inadequate translation of the scientific data into daily practice, with clinical judgment being established on expert opinion instead of the objective evaluation of valid scientific studies.

Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies

Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disease that affects children and adults. Until recently, the only Food and Drug Administration–approved systemic treatment option for patients with moderate-to-severe AD was systemic steroids, which are not recommended by current guidelines and are commonly associated with disease rebound.

Allergists on Social Media